Cheung Edward C, Hodax Jonathan D, Hsu Wellington K, Williams Seth K, Smith Harvey E, Lansdown Drew A, Feeley Brian T
Instr Course Lect. 2020;69:273-288.
The frequency of use of "biologics," including platelet-rich plasma (PRP), bone morphogenetic protein (BMP), and stem cell therapies in the treatment of orthopaedic conditions has significantly increased over the past few decades. The use of PRP and stem cells has been proposed for a wide variety of conditions including knee and hip osteoarthritis (OA), tendon strains and tendinopathies, muscle strains, and acute and chronic soft-tissue injuries. It has also been proposed for use in the enhancement of healing during surgical treatments. BMP has seen use in promoting fracture union and spinal fusion and has been researched as an adjunct in other procedures as well. The current state of the literature in the use and support of these biologics is outlined here.
在过去几十年中,包括富血小板血浆(PRP)、骨形态发生蛋白(BMP)和干细胞疗法在内的“生物制剂”在骨科疾病治疗中的使用频率显著增加。PRP和干细胞已被提议用于多种病症,包括膝关节和髋关节骨关节炎(OA)、肌腱拉伤和肌腱病、肌肉拉伤以及急慢性软组织损伤。它还被提议用于在手术治疗期间促进愈合。BMP已被用于促进骨折愈合和脊柱融合,并且也作为其他手术的辅助手段进行了研究。本文概述了这些生物制剂使用和支持方面的文献现状。